Study S002717

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasiglifam (TAK-875) Compared to Placebo as Add-on to Preexisting Antihyperglycemic Therapy Over 16 Weeks With 36-week Extension in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or Stage 5 on Dialysis

ClinicalTrials.gov record

Registration

Registration: NCT02015780
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: WITHDRAWN
Enrollment: 0
Start: 2013-12
Primary completion: 2016-01
Lead sponsor: Takeda
Conditions: Type 2 Diabetes Mellitus; Chronic Kidney Disease
Interventions: DRUG:Fasiglifam; DRUG:Placebo; DRUG:Antihyperglycemic therapy
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1146-5546; EUDRACT_NUMBER:2013-003414-40

Registered primary outcomes

Change from Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 [Baseline and Week 16]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.